Table 3 Comparison of the ongoing phase III trials of PET-guided dCRT in esophageal cancer: ESO-Shanghai 12 vs SCOPE 2
ESO-Shanghai 12 (the current study) | SCOPE 2 | ||
|---|---|---|---|
Country | China | UK | |
No. of Patients | 634 | 584 | |
Study starting year | 2018 | 2016 | |
Pathology | SCC | AC/SCC | |
Radiation technique | IMRT | IMRT | |
Radiation field | IFI | ENI | |
Chemotherapy prior to PET 2 | Concurrent DDP + PTX * 2 cycles | Induction DDP + CAP * 1 cycle | |
Radiotherapy prior to PET 2 | 50.4 Gy/28 Fx | No | |
PET timing | Day of RT to 50.4 Gy/28 Fx ± 3 days | Day 14 | |
Metabolic parameters and cutoff | PET 2 SUVmax > 4 | △SUVmax ≥ 35% | |
Treatment posterior to intern PET | Responder | RT up to 50.4 Gy/28 Fx + chemotherapy (consolidative DDP + PTX * 2 cycles) | RT (50 Gy/25 Fx) + chemotherapy (concurrent DDP + CAP * 3 cycles) |
RT (60 Gy/25 Fx) + chemotherapy (concurrent DDP + CAP * 3 cycles) | |||
Non-responder | RT up to 61.2 Gy/34 Fx + chemotherapy (consolidative DDP + PTX * 2 cycles) | RT (50 Gy/25 Fx) + chemotherapy (concurrent weekly PTX + CBP) | |
RT (50 Gy/25 Fx) + chemotherapy (concurrent weekly PTX + CBP) | |||
Primary outcomes | 2y OS in PET/CT non-responder | 2y TIFFS in SCC | |
2y OS in all subjects | 2y OS in SCC | ||
– | 2y TIFFS in SCC switching chemotherapy | ||
– | 2y TIFFS in AC | ||
– | 2y TIFFS in AC switching chemotherapy | ||